J147 is a synthetic small molecule, a curcumin derivative designed at the Salk Institute and now owned by Abrexa Pharmaceuticals. It is not a peptide. A completed Phase 1 trial established safety and pharmacokinetics in humans, and a Phase 2 acute-stroke trial is currently recruiting, making J147 unusually far along in human development compared with most compounds this site covers, but no completed human trial has yet tested whether it actually works, for stroke, Alzheimer’s disease, or any other indication.
Ask about J147
Research snapshot
| Peptide category | Not a peptide: synthetic small molecule, curcumin derivative |
| Primary research interest | Acute ischemic stroke neuroprotection (current Phase 2 focus); originally developed for Alzheimer’s disease |
| Highest available evidence | Completed human Phase 1 safety/pharmacokinetics trial; Phase 2 acute-stroke efficacy trial recruiting |
| Human research available | Yes, for safety/PK; no completed human efficacy trial for any indication |
| Development status | Phase 2 (JUMPSTART, acute ischemic stroke, recruiting) |
| Regulatory status | Investigational; not approved for human use anywhere |
Technical identity
| Primary name | J147 |
| Alternative names | J 147; CAD-31 precursor compound; J147 curcumin derivative |
| Peptide sequence | Not applicable: this is a small molecule, not a peptide |
| Amino-acid length | Not applicable |
| Molecular formula | Not independently re-verified in this pass; consult a chemical database directly |
| Molecular weight | Not independently re-verified in this pass |
| CAS Registry Number | Not independently re-verified in this pass |
| PubChem CID | Not independently re-verified in this pass |
| UNII | Not reliably established |
| DrugBank ID | Not listed |
| Chemical modifications | Not applicable in the peptide sense, a curcumin-derivative small molecule |
| Peptide class | Not a peptide: curcumin-derivative small molecule |
| Primary biological target | Mitochondrial ATP synthase (reported inhibition), with downstream effects on cellular NAD+ and acetyl-CoA levels |
| Developer or originator | David Schubert and Pamela Maher’s laboratory, Salk Institute; now owned by Abrexa Pharmaceuticals, Inc. |
| Development status | Phase 2 (acute ischemic stroke) |
What it is
J147 is a synthetic small molecule, a curcumin derivative, designed by David Schubert and Pamela Maher’s laboratory at the Salk Institute using a phenotypic screening approach in aged mice rather than starting from a single known drug target. It is not a peptide. It is now owned by Abrexa Pharmaceuticals, Inc., which is running its human clinical development program.
Proposed mechanisms described in the reviewed literature include inhibition of mitochondrial ATP synthase and downstream effects on cellular NAD+ and acetyl-CoA levels, changes linked in mouse studies to reduced markers of brain aging; separately, J147 has been reported in mouse studies to stimulate markers of neurogenesis and improve dendritic structure.
Potential benefits and research applications
Neuroprotection in acute ischemic stroke, the indication now in human Phase 2 testing
J147’s proposed mitochondrial and neurogenic mechanisms are now being tested clinically in acute ischemic stroke patients undergoing endovascular clot removal, in the JUMPSTART Phase 2 trial. This is a safety-and-dose-finding study with imaging and clinical outcomes as secondary endpoints, and it has not reported results.
Evidence: is being investigated in an ongoing human Phase 2 trial (Tier 2, registered but unpublished human trial); has not been established as effective, since the trial has not reported results.
Alzheimer’s disease and broader neuroprotection, supported only by mouse and cell-culture data so far
J147 was originally identified and developed around proposed benefits in Alzheimer’s disease, based on mouse studies showing reduced markers of brain aging, increased neurogenesis markers, and improved dendritic structure, linked to inhibition of mitochondrial ATP synthase and changes in cellular NAD+ and acetyl-CoA levels.
Evidence: has been shown in mouse and cell-culture studies (Tier 3-4, published animal and laboratory evidence); has not been established in any human trial for Alzheimer’s disease specifically, and no such trial is currently registered.
Depression, diabetic neuropathy and fatty liver disease, preliminary mouse findings not yet in human testing
Additional mouse studies have reported benefits for J147 in models of depression, diabetic neuropathy and fatty liver disease, extending its proposed mechanism beyond neuroprotection alone.
Evidence: has been reported in mouse studies (Tier 3, published animal evidence); is being investigated only insofar as the compound’s general safety profile is now established in humans, not these specific indications.
Where its human development actually stands
A completed Phase 1 trial (Abrexa Pharmaceuticals, NCT03838185) gave single ascending oral doses of J147 to 64 healthy young and elderly volunteers in a randomized, double-blind, placebo-controlled design, to assess safety, tolerability and pharmacokinetics. Specific dose levels tested were not disclosed in the public trial record reviewed for this entry. This was a safety and PK study; it was not designed or powered to show any benefit.
As of this entry’s last check, a Phase 2 trial (NCT07430917, “JUMPSTART”) is recruiting, testing a single intravenous bolus of a J147 injectable formulation, given alongside mechanical thrombectomy, in patients with acute ischemic stroke undergoing endovascular clot removal. This is a safety-and-dose-finding study with imaging and clinical outcome measures as secondary endpoints; it has not reported results.
No completed human efficacy trial for J147, in stroke, Alzheimer’s disease, or any other indication, was located for this entry. Everything published about a benefit in Alzheimer’s disease, depression, diabetic neuropathy or fatty liver disease is a mouse or cell-culture finding.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate. The only completed human trial for J147 measured safety and pharmacokinetics, not benefit, and did not publicly disclose specific dose levels.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| Phase 1 safety and pharmacokinetics (healthy young and elderly volunteers) | Oral | Single ascending doses; specific mg levels not disclosed in the public trial record reviewed | Single dose per cohort | Not specified | Registered, completed human trial (NCT03838185) |
| Phase 2, acute ischemic stroke (JUMPSTART, alongside endovascular thrombectomy) | Intravenous bolus | Not yet disclosed (dose-finding) | Single IV bolus | Trial ongoing, recruiting since July 2026 | Registered, ongoing human trial (NCT07430917) |
| Cognitive/neuroprotective support, general (research-chemical/community use) | Oral | Varies by listing | Varies by listing | Varies by listing | Community/vendor reported: no published effective human dose exists to check against |
What is not known
Whether J147 does anything beneficial in a human being. The only completed human trial measured safety and pharmacokinetics, not efficacy, and the efficacy trial now underway has not reported results.
What dose, if any, will be carried forward from the ongoing Phase 2 stroke trial, and whether an effective human dose exists at all.
Whether any of the mouse findings in Alzheimer’s disease, depression or other indications will be tested in a dedicated human trial for those indications specifically, rather than the acute stroke population now being studied.
Frequently asked questions
What is J147?
J147 is a synthetic small molecule, a curcumin derivative designed at the Salk Institute using a phenotypic screening approach in aged mice. It is not a peptide, and it is now owned by Abrexa Pharmaceuticals.
How does J147 work?
Proposed mechanisms include inhibition of mitochondrial ATP synthase, changes in cellular NAD+ and acetyl-CoA levels, and stimulation of neurogenesis markers, all established so far in mouse and cell-culture studies.
What dosage has been studied in humans?
A completed Phase 1 trial gave single ascending oral doses to 64 healthy young and elderly volunteers, but specific dose levels were not disclosed in the public trial record reviewed for this entry.
What dosage commonly circulates online?
Research-chemical listings describe oral capsule or powder use at doses that vary by seller. No published effective human dose exists to check that figure against, since the only completed human trial measured safety and pharmacokinetics, not benefit.
Has J147 been studied in humans?
Yes. A Phase 1 safety and pharmacokinetics trial is complete, and a Phase 2 acute-stroke trial (JUMPSTART) is currently recruiting. No completed human efficacy trial exists yet.
Is J147 approved for use?
No. It is investigational and not approved for human use anywhere.
What routes of administration are reported?
The Phase 1 trial used oral dosing; the ongoing Phase 2 stroke trial uses an intravenous bolus formulation.
Does J147 treat Alzheimer’s disease?
This has not been established. The Alzheimer’s-related findings are entirely from mouse and cell-culture studies; no dedicated human Alzheimer’s trial for J147 is currently registered.
What side effects have been reported?
The completed Phase 1 trial assessed safety and tolerability, but specific results were not detailed in the public record reviewed for this entry.
What remains unknown about J147?
Whether it does anything beneficial in a human being, since the only completed trial measured safety, not efficacy; what dose the ongoing stroke trial will settle on; and whether its mouse findings in other indications will ever reach dedicated human trials.
Bottom line
J147 stands out for having a real, dated, active human clinical development program, a completed Phase 1 safety trial and a recruiting Phase 2 stroke trial, further along than most compounds this site covers. But “further along” does not mean proven: the only completed human trial measured safety and pharmacokinetics, not whether the drug actually works, and every benefit claim for Alzheimer’s disease, depression, diabetic neuropathy or fatty liver disease remains a mouse or cell-culture finding awaiting its own dedicated human trial.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| Cognitive/neuroprotective support, general | Oral | Varies by listing | Varies by listing | Varies by listing |
Circulating research-chemical listings for J147 describe oral capsule or powder use at doses that vary by seller. The completed human trial for this compound tested single ascending oral doses in a controlled clinical setting without publicly disclosing the dose levels used, and it measured safety and blood levels, not any beneficial effect. There is no published effective human dose for any purpose to check a circulating figure against.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Sources
- Abrexa Pharmaceuticals, Inc. Phase 1, randomized, double-blind, placebo-controlled single ascending oral dose study of J147 in healthy young and elderly volunteers. Completed 2020. Safety and PK only. NCT03838185
- Abrexa Pharmaceuticals, Inc. Phase 2, randomized, placebo-controlled, double-blind, adaptive study of intravenous J147 combined with endovascular therapy in acute ischemic stroke (JUMPSTART). Recruiting, started 2026-07-22. NCT07430917
- Prior M, et al. Selecting for neurogenic potential as an alternative for Alzheimer's disease drug discovery. Alzheimers Dement 2016;12(6):678-86. Mouse study, memory and neurogenesis findings, Salk Institute. PMID 27149904
Live registry status
These are the registered trials this page cites, pulled from ClinicalTrials.gov and refreshed automatically. Status and dates are what the registry currently shows. Listing a trial here does not mean it produced a positive result.
| Trial | Phase | Status | Sponsor | Enrolled | Primary completion | Registry updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of J147 in Acute Ischemic Stroke NCT07430917 | Phase 2 | Recruiting | Abrexa Pharmaceuticals, Inc. | 196 | Mar 1, 2028 | Aug 24, 2026 |
| Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147 NCT03838185 | Phase 1 | Completed | Abrexa Pharmaceuticals, Inc. | 64 | Feb 1, 2020 | Sep 3, 2020 |
Compare J-147 with related compounds
Research area: Neuro and cognitive.